Amyotrophic Lateral Sclerosis (ALS) Clinical Trial
Official title:
Paired Stimulation to Increase Cortical Transmission to Hand Muscles: Pilot Study
NCT number | NCT02469675 |
Other study ID # | HAR-15-001 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 2015 |
Est. completion date | July 31, 2018 |
Verified date | September 2018 |
Source | Bronx VA Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Most neurological injuries such as spinal cord injuries (SCI) and amyotrophic lateral
sclerosis (ALS) spare a portion of nerve circuitry. Strengthening spared nerve circuits may
be an important method to improve functional recovery.
In this study, the investigators aim to use non-invasive magnetic and electrical stimulation
to strengthen motor circuits between the brain and hands. Magnetic stimulation will be used
over the motor cortex (scalp). Two methods of electrical stimulation will be compared:
stimulation of the median nerve at the wrist; or direct stimulation of the cervical spinal
cord across the skin on the back of the neck. Several different combinations of magnetic and
electrical stimulation will be compared to find the conditions that best strengthen nerve
circuits between the brain and hands - "Fire Together, Wire Together".
PLEASE NOTE, THIS IS A PRELIMINARY STUDY. This study is testing for temporary changes in
nerve transmission and hand function. THERE IS NO EXPECTATION OF LONG-TERM BENEFIT FROM THIS
STUDY. If we see temporary changes in this study, then future studies would focus on how to
prolong that effect.
Status | Completed |
Enrollment | 39 |
Est. completion date | July 31, 2018 |
Est. primary completion date | July 31, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Males or females age 21-65 years; - No history of serious neurological injury or disease; OR - Chronic (>12 months since injury) incomplete SCI between levels C2-C8 or diagnosis of definite or probable ALS; - Incomplete weakness of left or right hand muscles: score of 3 or 4 (out of 5) on manual muscle testing of finger extension, finger flexion, or finger abduction; - Detectable F-wave responses of the left or right abductor pollicis brevis muscle to median nerve stimulation; - Detectable motor evoked potentials in left or right abductor pollicis brevis muscle to transcranial magnetic stimulation. Exclusion Criteria: - Multiple spinal cord lesions; - History of seizures; - Ventilator dependence or patent tracheostomy site; - Use of medications that significantly lower seizure threshold, such as tricyclic antidepressants, amphetamines, neuroleptics, dalfampridine, and bupropion; - History of stroke, brain tumor, brain abscess, or multiple sclerosis; - History of moderate to severe head trauma (loss of consciousness for greater than one hour or evidence of brain contusion or hemorrhage or depressed skull fracture on prior imaging); - History of implanted brain/spine/nerve stimulators, aneurysm clips, ferromagnetic metallic implants, or cardiac pacemaker/defibrillator; - Significant coronary artery or cardiac conduction disease; - Recurrent history over the last 6 months of autonomic dysreflexia; - History of bipolar disorder; - History of suicide attempt; - Active psychosis; - Heavy alcohol consumption (greater than equivalent of 5 oz of liquor) within previous 48 hours; - Open skin lesions over the face, neck, shoulders, or arms; - Pregnancy; - Unsuitable for study participation as determined by study physician. |
Country | Name | City | State |
---|---|---|---|
United States | James J. Peters VA Medical Center, Bronx, NY | Bronx | New York |
Lead Sponsor | Collaborator |
---|---|
Bronx VA Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in motor evoked potential (MEP) amplitude of the abductor pollicis brevis (APB) muscle response to single pulses of TMS | Assessed pre, then 0, 15, 30, and 90 minutes post-intervention. | ||
Primary | Hand dexterity | Timed performance on a grooved pegboard task. | Assessed pre, then 0, 15, 30, and 90 minutes post-intervention. | |
Primary | Safety and tolerability | Vital signs are monitored throughout procedure; symptoms and degree of pain/discomfort are checked frequently. | Assessed periodically during each session. | |
Secondary | Grip strength | Strength will be quantified using hand-held wireless dynamometry. | Assessed pre, then 0, 15, 30, and 90 minutes post-intervention. | |
Secondary | Change in the duration of the 'cortical silent period' after TMS stimulation during APB contraction | Assessed pre, then 0, 15, 30, and 90 minutes post-intervention. | ||
Secondary | F-wave responses of the APB muscle | Assessed pre, then 0, 15, 30, and 90 minutes post-intervention. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02365922 -
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
|
||
Completed |
NCT01699451 -
DNA, Blood and Skin Cell Repository for Research on ALS and Related Neurodegenerative Disorders at Mayo Clinic Florida
|
||
Completed |
NCT04577404 -
Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 3 | |
Terminated |
NCT03580616 -
Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Completed |
NCT02118805 -
Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
|
||
Completed |
NCT01884571 -
Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Completed |
NCT00244244 -
A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS
|
Phase 2 | |
Active, not recruiting |
NCT00420719 -
Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)
|
N/A | |
Completed |
NCT02936635 -
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
|
Phase 3 | |
Withdrawn |
NCT04055532 -
Biomarkers in Neurodegenerative Diseases
|
||
Completed |
NCT03645031 -
Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease
|
N/A | |
Completed |
NCT01786603 -
Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Completed |
NCT02559869 -
Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis
|
||
Completed |
NCT01592552 -
A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery
|
||
Completed |
NCT00403104 -
Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Recruiting |
NCT02424669 -
Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients
|
N/A | |
Completed |
NCT02017912 -
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
|
Phase 2 | |
Completed |
NCT01366027 -
PRISM Registry: Pseudobulbar Affect Registry Series
|
N/A | |
Completed |
NCT00330681 -
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
|
Phase 3 | |
Completed |
NCT00876772 -
Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2/Phase 3 |